Tango Therapeutics (TNGX) Earnings Date & Reports

Key Takeaways

• Tango Therapeutics (TNGX) reported financial results for the third quarter ended September 30, 2026, on November 3, 2026, its first full quarter after the conclusion of its Gilead collaboration.
• Collaboration revenue has effectively wound down to zero following the 2025 truncation of the Gilead partnership, shifting attention to clinical execution and operating expense discipline.
• Consensus estimates had modeled a net loss of roughly $0.35 per share for the quarter, following a $0.37 per-share loss reported in the second quarter of 2026.
• The company entered the quarter with approximately $1.0 billion in cash, cash equivalents, and marketable securities after a roughly $651 million equity raise earlier in 2026, supporting an operating runway into 2028.
• Investors are closely watching for initial Phase 1/2 safety and efficacy data from vopimetostat combination studies and the TNG456 program, both anticipated in 2026.
• For more context on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore the additional pages available for Tango Therapeutics.
• You can also explore Trending AI Robots to discover AI-driven trading strategies currently drawing attention across the market.

Earnings Context and Why It Matters

Tango Therapeutics is a clinical-stage biotechnology company using the genetic principle of synthetic lethality to develop precision cancer medicines. Because it has no approved products, its quarterly results are less about revenue and more about cash burn, pipeline progress, and clinical catalysts. The third quarter of 2026 marks a transitional period: the Gilead collaboration that once supplied collaboration revenue has fully concluded, leaving operating expenses — led by research and development (R&D) — as the primary financial driver. With lead candidates including the MTAP (methylthioadenosine phosphorylase)-selective PRMT5 (protein arginine methyltransferase 5) inhibitor vopimetostat advancing toward pivotal trials, investors are evaluating whether the company can convert its strengthened balance sheet into clinical milestones.

Reported Results

Tango reported results for the third quarter ended September 30, 2026, on November 3, 2026. Collaboration revenue remained at zero, consistent with the prior quarter and reflecting the 2025 conclusion of the Gilead collaboration, which had previously contributed the bulk of the company's top line. R&D expenses have continued to rise as the company accelerates the vopimetostat and TNG456 clinical programs, while general and administrative costs have also trended higher on personnel-related and share-based compensation expenses.

Entering the report, consensus estimates had called for a net loss of roughly $0.35 per share and revenue near $3.28 million, though the revenue figure had become largely symbolic given the winding down of collaboration income. In the prior quarter, Tango posted a $0.37 per-share loss, missing the consensus estimate of about $0.32. The company's most important financial metric remains its cash position, which stood near $1.0 billion after a mid-2026 equity offering — a buffer intended to fund operations into 2028.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. For biotech names like TNGX, the screener can help surface breakout candidates, trending equities, and emerging trade ideas more efficiently than manual screening. Consider exploring the AI Screener to see how it can streamline your market research.

Market Reaction and Investor Sentiment

Sentiment around TNGX has been shaped less by its income statement and more by its clinical narrative. The stock has historically shown sharp post-earnings moves, reflecting investor sensitivity to pipeline updates and cash runway commentary rather than quarterly losses, which are expected for a clinical-stage company. Heading into the report, attention centered on whether management would reaffirm its 2026 clinical milestones — including initial data from vopimetostat combinations with RAS(ON) inhibitors and the TNG456 program — and on any refinement of the registrational strategy for vopimetostat. The post-earnings price reaction is likely to hinge on these catalysts and on the company's latest operating expense and cash guidance.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should focus on a handful of clearly identifiable catalysts rather than near-term profitability. The most significant is the initial Phase 1/2 safety and efficacy data from vopimetostat combinations with daraxonrasib and zoldonrasib, expected in 2026. Management has indicated these results may help define a path toward a pivotal trial in first-line pancreatic cancer.

Separately, Tango is advancing TNG456, a PRMT5 inhibitor designed for central nervous system (CNS) cancers including glioblastoma, with initial monotherapy data also anticipated in 2026. An additional combination study of vopimetostat with ERAS-0015 is expected to begin in the second half of 2026.

On the financial side, the key variables are the pace of R&D spending and the durability of the cash runway. With roughly $1.0 billion in cash and marketable securities and guidance targeting funding into 2028, the company retains flexibility, but rising clinical costs could pressure the timeline if trials expand. Investors should monitor expense trends, milestone timing, and any updates to the registrational strategy, while keeping in mind that clinical-stage biotech remains inherently high-risk.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations